title: Lipopolysaccharides from Legionella and Rhizobium stimulate mouse bone marrow granulocytes via Toll-like receptor 2.
abstract: Lipopolysaccharide (LPS) derived from enterobacteria elicit in several cell types cellular responses that are restricted in the use of Toll-like receptor 4 (TLR4) as the principal signal-transducing molecule. A tendency to consider enterobacterial LPS as a prototypic LPS led some authors to present this mechanism as a paradigm accounting for all LPSs in all cell types. However, the structural diversity of LPS does not allow such a general statement. By using LPSs from bacteria that do not belong to the Enterobacteriaceae, we show that in bone marrow cells (BMCs) the LPS of Rhizobium species Sin-1 and of three strains of Legionella pneumophila require TLR2 rather than TLR4 to elicit the expression of CD14. In addition, exposure of BMCs from TLR4-deficient (C3H/HeJ) mice to the lipid A fragment of the Bordetella pertussis LPS inhibits their activation by the Legionella lipid A. The data show selective action of different LPSs via different TLRs, and suggest that TLR2 can interact with many lipid A structures, leading to either agonistic or specific antagonistic effects.
authors.affiliation: Lymphocyte development, URA-1961 of the National Center for Scientific Research, Pasteur Institute, Paris, France.
authors.forename: Robert
authors.initials: R
authors.lastname: Girard
authors.forename: Thierry
authors.initials: T
authors.lastname: Pedron
authors.forename: Satoshi
authors.initials: S
authors.lastname: Uematsu
authors.forename: Viviane
authors.initials: V
authors.lastname: Balloy
authors.forename: Michel
authors.initials: M
authors.lastname: Chignard
authors.forename: Shizuo
authors.initials: S
authors.lastname: Akira
authors.forename: Richard
authors.initials: R
authors.lastname: Chaby
mesh_terms: D000818:Animals; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology*; D016905:Gram-Negative Bacterial Infections / Q000276:immunology* / Q000378:metabolism; D006098:Granulocytes / Q000187:drug effects / Q000276:immunology*; D016952:Legionella pneumophila / Q000276:immunology / Q000378:metabolism; D008050:Lipid A / Q000276:immunology / Q000494:pharmacology; D018950:Lipopolysaccharide Receptors / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology* / Q000494:pharmacology; D008562:Membrane Glycoproteins / Q000172:deficiency / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011956:Receptors, Cell Surface / Q000172:deficiency / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D012231:Rhizobium / Q000276:immunology / Q000378:metabolism; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors
chemical_list: D008050:Lipid A; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors